Friedreich Ataxia

Friedreich ataxia is a difficult-to-diagnose inherited mitochondrial disease causing progressive ataxia, cardiomyopathy and scoliosis, with symptoms split across specialities that delay a single-gene diagnosis.

About Friedreich Ataxia

In numbers

Friedreich ataxia affects an estimated 4,000 to 7,000 people in the USA, around 2 per 100,000 in European-ancestry populations.
Incidence is about 1 in 50,000 live births in European-ancestry populations, with a carrier frequency of 1 in 60 to 110.
A 2025 Komodo claims analysis identified only 652 diagnosed patients over a seven-year period, well below the estimated prevalent pool, pointing to substantial under-coding.

Special details

Prevalence is concentrated in populations of European ancestry; the disease is markedly rarer in East Asian and sub-Saharan African populations.
In the claims-identified cohort, mean patient age was 33.2 years, with a slight female preponderance at 51.4 percent.
Classical onset falls in the first two decades of life, while late-onset and very-late-onset forms present from the mid-twenties into the fifth decade.

Signs and symptoms of Friedreich Ataxia

Median delay from symptom onset to diagnosis is 3 to 5 years, often longer when cardiomyopathy or scoliosis appears before ataxia and routes patients through cardiology or orthopaedics first.

Progressive ataxia

Gait and limb ataxia is the presenting feature in most patients, usually the first sign that prompts investigation.

Hypertrophic cardiomyopathy

Affects 60 to 80 percent of patients and is the leading cause of premature death.

Sensory neuropathy

Absent ankle reflexes and loss of vibration and joint-position sense reflect dorsal root ganglion degeneration.

Scoliosis

Affects around 60 percent of patients, often progressing in adolescence and sometimes requiring spinal fusion.

Diabetes mellitus

Insulin-deficient diabetes develops in 10 to 30 percent of patients as pancreatic beta cells are affected.

Key challenges from product development to launch

Strategy and Business

The wrong disease or indication selected for investment
Indications tackled in the wrong order due to shaky success estimates
R&D returns slipping below the cost of capital

Clinical Development

Trials delayed by low patient recruitment
High screen-failure rates that raise trial cost
Mixed cohorts that make the signals difficult to detect

HEOR, Access & Value

A value case that arrives too late or is underdeveloped
Eligible population under-counted, budget-impact case unsubstantiated
Approved by the regulator, delayed at HTA

Medical Affairs

Fragmented, differently-coded healthcare data
Diagnostic delay that is long and unequal
No shared evidence base across functions

Launch and Commercial

Launch planned without a view of the number of findable patients
Targeting too broad a population slows early uptake
RWE started too late to build the case

How Volv Global Helps

Strategy and Business

The earliest pipeline decisions carry lasting consequences: the wrong indication chosen, indications pursued in the wrong order, or capital committed where expected returns already trail its cost. Mistakes made this early are expensive to correct later.

inTrigue

Finds the true reachable population per candidate, so indication choices rest on evidence.

volv.global/finding-patients

inFlow

Adds probability-of-success and outcome evidence to help prioritise the pipeline.

volv.global/predict-patient-outcomes

Clinical Development

When patients cannot be found, recruitment stalls and the burn rate climbs. High screen-failure rates add further cost and delay, and a mixed cohort makes the results harder to interpret.

inTrigue

Finds the undiagnosed and mis-coded patients conventional feasibility misses, widening the recruitable pool.

volv.global/finding-patients

inCare

Surfaces diagnosed-but-hidden, trial-eligible patients already in the data, so sites enrol faster.

volv.global/stratifying-patient-cohorts

inFlow

Predicts who will progress or respond, enriching the cohort so the signal is not diluted.

volv.global/predict-patient-outcomes

HEOR, Access & Value

Without strong, timely evidence, payers can restrict access or cut the price. An under-characterised population weakens the budget case, and HTA approval demands more evidence than regulatory approval alone.

inFlow

Generates the real-world evidence and outcomes payers ask for, ahead of the submission deadline.

volv.global/predict-patient-outcomes

inTrigue

Finds the undiagnosed patients missing from the count, so the eligible population holds up under scrutiny.

volv.global/finding-patients

inCare

Surfaces the diagnosed-but-eligible patients who expand the eligible population count.

volv.global/stratifying-patient-cohorts

Medical Affairs

Healthcare data is fragmented across markets, so evidence has to be rebuilt market by market, slowing decisions. Time to an accurate diagnosis varies by who the patient is and where they are treated.

inTrigue

Works across fragmented, differently-coded data by design, so insight holds up country to country without a rebuild.

volv.global/finding-patients

inAdvance

Detects patients ahead of typical diagnosis, closing the gap in awareness and pathway that drives unequal delay.

volv.global/earlier-detection

Launch and Commercial

A launch planned without a view of findable patients is poorly resourced from day one. Targeting too broad a population slows early uptake, and real-world evidence gathered too late leaves little time to build a strong access dossier.